Zobrazeno 1 - 10
of 5 352
pro vyhledávání: '"SGLT2 inhibitors"'
Autor:
Francesco Loria, Pasquale Mone, Antonella Rispoli, Rosanna Di Fonzo, Daniele Masarone, Costantino Mancusi, Michele Correale, Antonio Vitullo, Michele Granatiero, Pietro Mazzeo, Valentina Mercurio, Francesco Fiore, Elena Di Sarro, Luigi Falco, Carmine Izzo, Alfonso Campanile, Nicola Virtuoso, Eugenio Stabile, Salvatore Bonanno, Giuseppe Dattilo, Carlo Gabriele Tocchetti, Gaetano Santulli, Carmine Vecchione, Michele Ciccarelli, Valeria Visco
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-14 (2024)
Abstract Background Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) represent a deep revolution of the therapeutic approach to heart failure (HF), preventing its insurgence but also improving the management of the disease and slowing its natural p
Externí odkaz:
https://doaj.org/article/62f52253e5614fe6bd6042fb67dd5779
Autor:
Farazul Hoda, Harsha Negi, Digvijaya Saini, Mawrah Arshad, Sidra Zayed, Mukesh Kumar Raut, Mohammad Anwar Habib, Mohd Akhtar, Abul Kalam Najmi
Publikováno v:
Exploration of Medicine, Vol 5, Iss 6, Pp 774-796 (2024)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are integral to diabetes treatment, facilitating renal glucose excretion and offering benefits in cardiovascular risk reduction, kidney function preservation, and weight management. However, their int
Externí odkaz:
https://doaj.org/article/628811c157224547a727cc658e36505f
Autor:
S. Yu. Martsevich
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 20, Iss 4, Pp 444-450 (2024)
The article briefly describes the stages of creating the main methods of acute myocardial infarction (MI) and its complications treatment. It is noted that currently existing clinical guidelines (CG) were formed at the end of the first decade of the
Externí odkaz:
https://doaj.org/article/545ddc485850496dbcd475debc20ad80
Autor:
Jiabin Zang, Jianwen Liang, Xiaocong Zhang, Dan Sang, Xinyue Duan, Zhenyu Wang, Wenbin Wei, Guifu Wu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Although sodium–glucose transport protein-2 (SGLT2) inhibitors (SGLT2i) do not increase the risk of acute kidney injury (AKI) in general, they may pose a risk in patients undergoing angiography. This prospective cohort study aimed to evalu
Externí odkaz:
https://doaj.org/article/6a6294a47a0a4551871ba9649e91141a
Publikováno v:
Cardiologia Hungarica, Vol 54, Iss 4, Pp 286-293 (2024)
Since the publication of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (HF), results of several randomized controlled clinical trials have been published that have a direct impact on day-to-day clinical pr
Externí odkaz:
https://doaj.org/article/98c017874e234ee6a567f280ee3d223b
Autor:
Ioan-Alexandru Minciună, Raluca Tomoaia, Dragos Mihăilă, Gabriel Cismaru, Mihai Puiu, Radu Roșu, Gelu Simu, Florina Frîngu, Diana Andrada Irimie, Bogdan Caloian, Dumitru Zdrenghea, Dana Pop
Publikováno v:
Current Issues in Molecular Biology, Vol 46, Iss 9, Pp 9607-9623 (2024)
Atrial cardiomyopathy and remodeling play pivotal roles in the development of atrial fibrillation (AF) and heart failure (HF), involving complex changes in atrial structure and function. These changes facilitate the progression of AF and HF by creati
Externí odkaz:
https://doaj.org/article/76e597fbc47444499e13ae1017817b42
Autor:
Arif Albulushi, Desmond Boakye Tanoh, Ahmed Almustafa, Nadya Al Matrooshi, Ronald Zolty, Brian Lowes
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-18 (2024)
Abstract Background Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited treatments. Sodium-glucos
Externí odkaz:
https://doaj.org/article/ad3d0b56410c49c29f17f77dcdea7fc7
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract New anti-diabetic medications, including glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 (SGLT2) inhibitors are recommended in guidelines to reduce cardio-renal events in type 2 diabetes mellitus (T2DM)
Externí odkaz:
https://doaj.org/article/dfd3377f831e447b8cbb28410fd97941
Publikováno v:
BMC Endocrine Disorders, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background International longitudinal studies have indicated an increasing incidence of diabetic ketoacidosis (DKA). We aim to examine the incident trends, demographic differences, length of stay and mortality for DKA in adults with type 1 d
Externí odkaz:
https://doaj.org/article/d2905f3a50b14f52ae970be85d47bcb0
Publikováno v:
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background/Objective The research on sodium-glucose cotransporter 2 (SGLT2) inhibitors has been increasing rapidly in the last decade, as well as indications for their use. This study aimed to analyze the methodological characteristics of cl
Externí odkaz:
https://doaj.org/article/0e87dbf34f5844d799cddc061482046c